Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
dc.contributor.author | Gore, M E | |
dc.contributor.author | Hariharan, S | |
dc.contributor.author | Porta, C | |
dc.contributor.author | Bracarda, S | |
dc.contributor.author | Hawkins, Robert E | |
dc.contributor.author | Bjarnason, G A | |
dc.contributor.author | Oudard, S | |
dc.contributor.author | Lee, S H | |
dc.contributor.author | Carteni, G | |
dc.contributor.author | Nieto, A | |
dc.contributor.author | Yuan, J | |
dc.contributor.author | Szczylik, C | |
dc.date.accessioned | 2012-01-10T22:40:35Z | |
dc.date.available | 2012-01-10T22:40:35Z | |
dc.date.issued | 2011-02-01 | |
dc.identifier.citation | Sunitinib in metastatic renal cell carcinoma patients with brain metastases. 2011, 117 (3):501-9 Cancer | en |
dc.identifier.issn | 0008-543X | |
dc.identifier.pmid | 20862748 | |
dc.identifier.doi | 10.1002/cncr.25452 | |
dc.identifier.uri | http://hdl.handle.net/10541/201530 | |
dc.description.abstract | In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open-label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. | |
dc.language.iso | en | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Brain Neoplasms | |
dc.subject.mesh | Carcinoma, Renal Cell | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Indoles | |
dc.subject.mesh | Kidney Neoplasms | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Pyrroles | |
dc.title | Sunitinib in metastatic renal cell carcinoma patients with brain metastases. | en |
dc.type | Article | en |
dc.contributor.department | Royal Marsden Hospital NHS Trust, London, United Kingdom. | en |
dc.identifier.journal | Cancer | en |
html.description.abstract | In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open-label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. |